Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly for YearsThe Motley Fool • 09/28/24
Prediction: Eli Lilly Will Dominate the Billion-Dollar Weight Loss Drug Market for This Key ReasonThe Motley Fool • 09/27/24
Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat TreatmentsBenzinga • 09/25/24
New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitisPRNewsWire • 09/25/24
Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's DiseasePRNewsWire • 09/24/24
Investing in This Healthcare Stock Could Be Like Catching Nvidia at the Dawn of the AI BoomThe Motley Fool • 09/22/24
Prediction: This Is What Eli Lilly Stock Will Do Next (Hint: It's Not a Stock Split)The Motley Fool • 09/21/24
Eli Lilly: Sticking With A $1000 Target Ahead Of Q3 Earnings, New Trading RangeSeeking Alpha • 09/21/24
Is Eli Lilly Stock A Buy After Snagging Approval For A New Eczema Drug?Investors Business Daily • 09/19/24